Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedincellMDCLF +393.00%77 Price-to-Tangible-Book is 347.37 as of Jul. 14, 2026, which is 820% above its 10-year median of 37.74. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review. Among 1,150 Biotechnology companies, Medincell ranks worse than 99.65% on this metric.
As of today (2026-07-14), Medincell's share price is $34.39. Medincell's Tangible Book per Share of Mar. 2026 for the quarter that ended in Mar. 2026 was $0.10. Hence, Medincell's Price to Tangible Book Ratio of today is 347.37.
The historical rank and industry rank for Medincell's Price-to-Tangible-Book or its related term are showing as below:
MDCLF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 26.15 Med: 37.74 Max: 318.82
Current: 312.64
During the past 11 years, Medincell's highest Price to Tangible Book Ratio was 318.82. The lowest was 26.15. And the median was 37.74.
MDCLF's Price-to-Tangible-Book is ranked worse than 99.65% of 1150
companies
in the Biotechnology industry
Industry Median: 3.285
vs MDCLF: 312.64
A closely related ratio is called PB Ratio. As of today, Medincell's share price is $34.39. Medincell's Book Value per Sharefor the quarter that ended in Mar. 2026 was $0.10. Hence, Medincell's P/B Ratio of today is 347.37.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Medincell Price-to-Tangible-Book Related Terms
Medincell Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Medincell's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Medincell's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Medincell's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
What does a Price-to-Tangible-Book of 347.37 mean?
Medincell (MDCLF) has a Price-to-Tangible-Book of 347.37 as of Jul. 14, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Medincell and its competitors. This is 820% above median its historical median of 37.74. Over the past decade, Medincell's Price-to-Tangible-Book has ranged from 26.15 to 318.82. According to the industry distribution chart, Medincell ranks #1146 out of 1150 companies in the Biotechnology industry, placing it in the top 99.7%.
Is Medincell's Price-to-Tangible-Book too high?
Medincell's current Price-to-Tangible-Book of 347.37 is 820% above median its 10-year median of 37.74. Over the past 10 years, this metric has ranged from a low of 26.15 to a high of 318.82. The Biotechnology industry median Price-to-Tangible-Book is 3.29. Medincell's value of 347.37 is 10474.4% above this industry median. Based on the distribution chart, Medincell ranks #1146 out of 1150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #1146 out of 1150 companies for Price-to-Tangible-Book. This places Medincell in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.29. Medincell's value of 347.37 is 10474.4% above this benchmark. Historically, Medincell's own Price-to-Tangible-Book has ranged from 26.15 to 318.82 over the past decade. While the company's 10-year median is 37.74 vs. the industry median of 3.29, Medincell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.29, based on 1,150 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Price-to-Tangible-Book of 347.37 is 10474.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Medincell and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Price-to-Tangible-Book is 347.37, which is 820% above median its own 10-year median of 37.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Price-to-Tangible-Book of 347.37. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Price-to-Tangible-Book is 347.37, which is 820% above median its 10-year median of 37.74 and 10474.4% above the Biotechnology industry median of 3.29. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Medincell (MDCLF), the current Price-to-Tangible-Book is 347.37 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Price-to-Tangible-Book: 347.37 (820% above median its 10-year median of 37.74)
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 10474.4% above the Biotechnology median (#1146 of 1150)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
